Haydar Frangoul, MD, on Weighing Gene Therapy Against Haploidentical Transplant for Sickle Cell Disease
The medical director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed the pros and cons of potentially curative treatment options for SCD.
Haydar Frangoul, MD, on Insurance and Fertility Concerns After Sickle Cell Gene Therapy
The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed unmet needs that remain after gene therapy approval for SCD.
Haydar Frangoul, MD, on Landmark Gene Editing Exa-Cel Approval for SCD
The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed his experience with and reaction to the approval of Casgevy.
Haydar Frangoul, MD, on Clinically Meaningful and QoL Improvements in Sickle Cell With Exa-Cel
The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed new data from CLIMB-121 presented at ASH 2023 supporting Casgevy's approval.